What question did this study set out to answer?

To evaluate the effects of a 20-week dosing schedule of faricimab in patients with wet age-related macular degeneration.

February 11, 2026Open Access

Potential 20-week Faricimab Dosing in Wet Age-Related Macular Degeneration

Key Points

To evaluate the effects of a 20-week dosing schedule of faricimab in patients with wet age-related macular degeneration.
Evaluated patients with nAMD in TENAYA/LUCERNE trials
Analyzed outcomes over a 2-year period
Assessed the potential for extended dosing intervals based on protocol allowances.
Patients on extended dosing maintained robust disease control for 2 years.
56% of patients could potentially benefit from every-20-week dosing if permitted.

Abstract

Patients with nAMD in TENAYA/LUCERNE always on extended faricimab dosing (≥12-weeks) achieved robust disease control throughout 2 years. Additionally, 56% of patients could have potentially extended to every-20-week dosing had the protocol allowed.

Potential 20-week Faricimab Dosing in Wet Age-Related Macular Degeneration

Key Points

Abstract

Cite This Study